---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-049470"
form_type: "8-K"
ticker: "ATNM"
cik: "0001388320"
company_name: "Actinium Pharmaceuticals, Inc."
filed_at: "2021-09-23T23:59:59+00:00"
generated_at: "2026-06-29T01:45:06.928944+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Actinium appoints Swaminathan as Chief Business Officer, Desai as CMO; Berger resigns

## Summary
- Mark Berger resigns as CMO effective Sept 24, 2021; no disagreement with company.
- Arun Swaminathan, Ph.D., appointed Chief Business and Commercial Officer; previously at Alteogen, BMS.
- Avinash Desai, M.D., promoted to CMO from EVP Clinical Development; will lead BLA filing for Iomab-B.
- Paul Diamond, Ph.D., appointed VP Patent and Legal Counsel; 20+ years IP experience.
- Phase 3 SIERRA trial enrollment complete; commercial planning for Iomab-B begins.

## SEC filing metadata
- accession: 0001213900-21-049470
- form_type: 8-K
- ticker: ATNM
- cik: 0001388320
- company_name: Actinium Pharmaceuticals, Inc.
- filed_at: 2021-09-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/0001213900-21-049470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/ea147815-8k_actinium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-049470
- JSON: https://secwatch.observer/filing/0001213900-21-049470.json
- Plain text: https://secwatch.observer/filing/0001213900-21-049470.txt

## Key facts
- Executive change
  Mark S. Berger resigned as Chief Medical Officer at Actinium Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: Dr. Mark S. Berger, the Chief Medical Officer of Actinium Pharmaceuticals, Inc. (the “Company”), notified the Company that he will be resigning effective as of September 24, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/0001213900-21-049470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.